Results 21 to 30 of about 31,314 (297)

Anesthetic management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A case report

Saudi Journal of Anaesthesia, 2023
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly influence overall and disease-free survival in selected patients suffering from peritoneal surface malignancies (PSMs).
Nilanjana Howbora, Swaraj J Sonowal, Tridip J Borah, Sonai D Kakati, Anupam Das, Marie Ninu, Dokne Chintey   +6 more
doaj   +1 more source

Postoperative complications and critical care management after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: A systematic review of the literature

World Journal of Critical Care Medicine, 2022
BACKGROUND Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a comprehensive treatment option performed for peritoneal surface malignancies. Postoperatively almost all patients are transferred to the intensive care unit
Anjana S Wajekar, S. Solanki, V. Patil
semanticscholar   +1 more source

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: our initial experience of implementation and detailed technique [PDF]

Ķazaķstannyṇ Klinikalyķ Medicinasy, 2019
Objective: The aim of this study is to present our initial implementation experience in peritoneal carcinomatosis treatment and the technical details of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the light of current ...
Talgat Uskenbayev, Altay Kerimkulov, Adilbek Mukazhanov, Meiram Mamlin, Rimbay Kaliyev   +4 more
doaj   +1 more source

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +4 more sources

Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting

International Journal of Hyperthermia, 2021
Purpose We aimed to determine the effects and possible mechanisms of hyperthermic intraperitoneal chemotherapy (HIPEC) in targeting ovarian cancer stem-like cells (CSCs).
Chao-Chih Wu, Yun-Ting Hsu, Chih-Long Chang   +2 more
doaj   +1 more source

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers

International Journal of Molecular Sciences, 2022
Most patients with epithelial ovarian cancers (EOCs) are at advanced stages (stage III–IV), for which the recurrence rate is high and the 5-year survival rate is low.
Pei-Qi Lim, I. Han, K. Seow, Kuo-Hu Chen
semanticscholar   +1 more source

Hyperthermic intraperitoneal chemotherapy after upfront cytoreductive surgery for stage III epithelial ovarian cancer: Follow-up of long-term survival. [PDF]

Acta Obstet Gynecol Scand
This study provides further evidence supporting the long‐term efficacy of HIPEC for the primary treatment of advanced ovarian cancer. The PCS‐HIPEC approach achieved superior survival outcomes when optimal cytoreduction was possible. Abstract Introduction The survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) has been well defined at
Lei Z, Wang Y, Fang R, Wang K, Tian J, Chen Y, Wang Y, Luo J, He J, Ding B, Yang X, Wang L, Cui S, Tang H, Chinese Peritoneal Oncology Study group (Gynecologic Oncology Study group).   +14 more
europepmc   +2 more sources

The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.

JAMA Surgery, 2021
Importance Studies on the prognostic role of hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei (PMP) are currently not available.
S. Kusamura, F. Barretta, Y. Yonemura, P. Sugarbaker, B. Moran, E. Levine, D. Goéré, D. Baratti, E. Nizri, D. Morris, O. Glehen, A. Sardi, P. Barrios, F. Quénet, L. Villeneuve, A. Gómez-Portilla, I. D. de Hingh, W. Ceelen, J. Pelz, P. Piso, S. González-Moreno, K. van der Speeten, M. Deraco   +22 more
semanticscholar   +1 more source

Is Cytoreductive Surgery Possible in Cervical Cancer Peritoneal Carcinomatosis?

Clinical Medicine Insights: Oncology, 2021
Background: The number of cases of cervical cancer with recurrence and peritoneal carcinomatosis is limited. In our study, we aimed to present the results of cytoreductive surgery hyperthermic intraperitoneal chemotherapy treatment and its 3-year early ...
Ozgul Duzgun, Murat Kalin
doaj   +1 more source

Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study

Journal of Clinical Oncology, 2021
PURPOSE The purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive surgery.
O. Zivanovic, D. Chi, Qin C Zhou, A. Iasonos, J. Konner, V. Makker, R. Grisham, Amy K Brown, S. Nerenstone, John P Diaz, E. Schroeder, C. Langstraat, V. Paroder, Y. Lakhman, Krysten Soldan, K. Su, G. Gardner, V. Andikyan, Jianxia Guo, E. Jewell, K. L. Long Roche, T. Troso-Sandoval, S. Lichtman, L. Moukarzel, K. Dessources, N. Abu-Rustum, C. Aghajanian, W. Tew, J. Beumer, Y. Sonoda, R. O'Cearbhaill   +30 more
semanticscholar   +1 more source